Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene.

BACKGROUND Mutations that cause hypertrophic cardiomyopathy (HCM) have been identified in 9 genes that code proteins in the sarcomere. Previous reports have demonstrated that cardiac troponin I (cTnI) gene mutations may account for familial HCM; however, the clinical characteristics and prognosis of patients with HCM caused by cTnI gene mutations are not known. METHODS AND RESULTS We analyzed cTnI gene mutations in 130 unrelated probands with HCM and their families to clarify the genotype-phenotype correlations. We identified 25 individuals in 7 families with a Lys183 deletion (Lys183 del) mutation in exon 7 of the cTnI gene. The disease penetrance in subjects aged >20 years was 88% by echocardiography and 96% by ECG. Sudden death occurred in 7 individuals of 4 families at any age. Overall, 7 (43.8%) of 16 individuals aged >40 years had left ventricular systolic dysfunction, and 3 (18.8%) displayed dilated cardiomyopathy-like features. Of affected individuals, 4 of 5 individuals aged >40 years followed by echocardiography showed septal thinning and decreased fractional shortening during >5 years of follow-up. CONCLUSIONS The Lys183 del mutation in the cTnI gene in patients with HCM is associated with variable clinical features and outcomes. HCM caused by the Lys183 del mutation has a significant disease penetrance. This mutation is associated with sudden death at any age and dilated cardiomyopathy-like features in those aged >40 years. However, it remains unclear whether screening of families with HCM for this mutation will be useful in patient management and counseling.

[1]  M. Desai,et al.  Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.

[2]  H. Watkins,et al.  Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. , 1999, Cardiovascular Research.

[3]  M Hiroe,et al.  Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. , 1999, Biochemical and biophysical research communications.

[4]  A. Børglum,et al.  α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy , 1999 .

[5]  P. Powers,et al.  Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency. , 1999, Circulation research.

[6]  H. Watkins,et al.  Defective inhibitory properties of human cardiac troponin I mutants that cause familial hypertrophic cardiomyopathy (FHC) , 1998 .

[7]  A. Kisanuki,et al.  Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. , 1998, Circulation.

[8]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[9]  W. Mckenna,et al.  Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. , 1997, Circulation.

[10]  R. Solaro,et al.  The C Terminus of Cardiac Troponin I Is Essential for Full Inhibitory Activity and Ca2+ Sensitivity of Rat Myofibrils* , 1997, The Journal of Biological Chemistry.

[11]  M. Matsuzaki,et al.  Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy , 1997, Nature Genetics.

[12]  H. Watkins,et al.  Sudden death due to troponin T mutations. , 1997, Journal of the American College of Cardiology.

[13]  Y. Fujio,et al.  Novel missense mutation in cardiac troponin T gene found in Japanese patient with hypertrophic cardiomyopathy. , 1997, Journal of molecular and cellular cardiology.

[14]  I. Rayment,et al.  Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle , 1996, Nature Genetics.

[15]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[16]  J. V. Van Eyk,et al.  Altered interactions among thin filament proteins modulate cardiac function. , 1996, Journal of Molecular and Cellular Cardiology.

[17]  J. Seidman,et al.  Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[18]  A. Marian,et al.  Recent advances in the molecular genetics of hypertrophic cardiomyopathy. , 1995, Circulation.

[19]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[20]  A. Marian,et al.  Sudden cardiac death in hypertrophic cardiomyopathy , 1995 .

[21]  R. Shannon,et al.  Intravenous cocaine induces platelet activation in the conscious dog. , 1995, Circulation.

[22]  M. Komajda,et al.  Molecular basis of familial cardiomyopathies. , 1995, Circulation.

[23]  M. Crawford,et al.  Cardiac troponin I is a heart-specific marker in the Xenopus embryo: expression during abnormal heart morphogenesis. , 1994, Developmental biology.

[24]  Christine E. Seidman,et al.  α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.

[25]  A. Picard,et al.  Structure and regulation of the mouse cardiac troponin I gene. , 1994, The Journal of biological chemistry.

[26]  W. Roberts,et al.  Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[27]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[28]  A. Murphy,et al.  Troponin I isoform expression in human heart. , 1991, Circulation research.

[29]  K. Hastings,et al.  Structure and developmental expression of troponin I isoforms. cDNA clone analysis of avian cardiac troponin I mRNA. , 1991, The Journal of biological chemistry.

[30]  A. Strauss,et al.  Molecular cloning of rat cardiac troponin I and analysis of troponin I isoform expression in developing rat heart. , 1991, Biochemistry.

[31]  M. Frenneaux,et al.  Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. , 1990, Circulation.

[32]  J. Seidman,et al.  A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.

[33]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[34]  J. H. Collins,et al.  Amino acid sequence of bovine cardiac troponin I. , 1988, Biochemistry.

[35]  R. Bonow,et al.  Hypertrophic cardiomyopathy. , 1987, Disease-a-month : DM.

[36]  R. Bonow,et al.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). , 1987, The New England journal of medicine.

[37]  W. Roberts,et al.  Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. , 1982, Circulation.

[38]  W. Mckenna,et al.  Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. , 1981, The American journal of cardiology.

[39]  B. Maron,et al.  Hypertrophic cardiomyopathy: a discussion of nomenclature. , 1979, The American journal of cardiology.

[40]  J. Wilkinson,et al.  The amino acid sequence of rabbit cardiac troponin I. , 1976, The Biochemical journal.

[41]  A. Marian,et al.  Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of beta-myosin heavy chain mutations. , 1995, European heart journal.

[42]  S. Solomon,et al.  Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. , 1994, The Journal of clinical investigation.

[43]  W. Roberts,et al.  Causes of sudden death in competitive athletes. , 1986, Journal of the American College of Cardiology.